ORLANDO, Florida, July 6, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered cGMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies. Through a licencing agreement with Hemostemix Inc. (“Hemostemix”), Aspire is responsible for manufacturing and managing clinical trial activities including patient data collections and processing of […]
Aspire Health Science Announces US FDA Approval of IND Application Regarding Testing Proprietary ACT-20 Cellular Therapy Against COVID-19 Pneumonia
ORLANDO, Florida, June 1, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered cGMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is thrilled to announce that it has received IND approval from the U.S. FDA to test the Company’s proprietary cellular therapy, ACT-20, against moderate to […]
Aspire Announces Strategic Partnership with NeoProgen
ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc. NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing […]
New Filing – Cellular Therapy against COVID-19 Pneumonia
ORLANDO, Florida, March 31st, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered manufacturing facility specialized in the development and manufacturing of cell-based therapies, is pleased to announce that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA and Pre-CTA (Clinical Trial Application) with Health Canada. […]
